FI104639B - Expression av hepatitis B, S och PreS2 proteiner i metylotropiska jäster - Google Patents
Expression av hepatitis B, S och PreS2 proteiner i metylotropiska jäster Download PDFInfo
- Publication number
- FI104639B FI104639B FI892312A FI892312A FI104639B FI 104639 B FI104639 B FI 104639B FI 892312 A FI892312 A FI 892312A FI 892312 A FI892312 A FI 892312A FI 104639 B FI104639 B FI 104639B
- Authority
- FI
- Finland
- Prior art keywords
- gene
- pichia pastoris
- isolated
- dna
- aox1
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 134
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 32
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims description 30
- 208000002672 hepatitis B Diseases 0.000 title abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 60
- 239000002245 particle Substances 0.000 claims abstract description 26
- 230000000890 antigenic effect Effects 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 239000013612 plasmid Substances 0.000 claims description 93
- 239000013598 vector Substances 0.000 claims description 84
- 108020004414 DNA Proteins 0.000 claims description 80
- 239000012634 fragment Substances 0.000 claims description 74
- 230000001105 regulatory effect Effects 0.000 claims description 33
- 241000235058 Komagataella pastoris Species 0.000 claims description 29
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 29
- 241000700721 Hepatitis B virus Species 0.000 claims description 27
- 230000009466 transformation Effects 0.000 claims description 25
- 239000003550 marker Substances 0.000 claims description 19
- 101150069554 HIS4 gene Proteins 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 101150005709 ARG4 gene Proteins 0.000 claims description 7
- 241000235648 Pichia Species 0.000 claims description 7
- 230000001131 transforming effect Effects 0.000 claims description 7
- 101150061183 AOX1 gene Proteins 0.000 claims description 5
- 101150010882 S gene Proteins 0.000 claims description 4
- 101150014136 SUC2 gene Proteins 0.000 claims description 3
- 101100004044 Vigna radiata var. radiata AUX22B gene Proteins 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 2
- 102100036826 Aldehyde oxidase Human genes 0.000 claims 9
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 claims 9
- 101710093617 Dihydroxyacetone synthase Proteins 0.000 claims 5
- PVFDPMYXCZLHKY-MLLWLMKGSA-M sodium [(1R,2R,4aR,8aS)-2-hydroxy-5-[(2E)-2-[(4S)-4-hydroxy-2-oxooxolan-3-ylidene]ethyl]-1,4a,6-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl sulfate Chemical compound [Na+].C([C@@H]1[C@](C)(COS([O-])(=O)=O)[C@H](O)CC[C@]11C)CC(C)=C1C\C=C1/[C@H](O)COC1=O PVFDPMYXCZLHKY-MLLWLMKGSA-M 0.000 claims 4
- 101150066375 35 gene Proteins 0.000 claims 1
- 241000235342 Saccharomycetes Species 0.000 claims 1
- -1 p40 Proteins 0.000 claims 1
- 102100031673 Corneodesmosin Human genes 0.000 abstract description 17
- 101710139375 Corneodesmosin Proteins 0.000 abstract description 16
- 230000008569 process Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 238000006460 hydrolysis reaction Methods 0.000 description 33
- 230000007062 hydrolysis Effects 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 239000000523 sample Substances 0.000 description 22
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 18
- 108010025188 Alcohol oxidase Proteins 0.000 description 17
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 17
- 229960000723 ampicillin Drugs 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 241001288713 Escherichia coli MC1061 Species 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 10
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000011543 agarose gel Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 108010042407 Endonucleases Proteins 0.000 description 8
- 102000004533 Endonucleases Human genes 0.000 description 8
- 102000003960 Ligases Human genes 0.000 description 8
- 108090000364 Ligases Proteins 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 8
- 238000001502 gel electrophoresis Methods 0.000 description 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000002703 mutagenesis Methods 0.000 description 8
- 231100000350 mutagenesis Toxicity 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 229940063673 spermidine Drugs 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- 241000235070 Saccharomyces Species 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000012869 ethanol precipitation Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229910001868 water Inorganic materials 0.000 description 4
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 241000364057 Peoria Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 101150098466 rpsL gene Proteins 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Natural products OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
- 241001506991 Komagataella phaffii GS115 Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940120503 dihydroxyacetone Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 101150085823 hsdR gene Proteins 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000006151 minimal media Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- ARVQIYGIIOWVCP-UHFFFAOYSA-N 2-cyanoethyl dihydrogen phosphite Chemical compound OP(O)OCCC#N ARVQIYGIIOWVCP-UHFFFAOYSA-N 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100035893 CD151 antigen Human genes 0.000 description 1
- 101710118846 CD151 antigen Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000048120 Galactokinases Human genes 0.000 description 1
- 108700023157 Galactokinases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001149669 Hanseniaspora Species 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 101100351324 Homo sapiens PDPN gene Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100174763 Mus musculus Galk1 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102100037265 Podoplanin Human genes 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101000836384 Rattus norvegicus Serpin H1 Proteins 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241001105470 Valenzuela Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 101150012763 endA gene Proteins 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 101150041954 galU gene Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 101150101299 gene 4 gene Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 101150096208 gtaB gene Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010045897 polyalbumin Proteins 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 101150072534 sbcB gene Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Claims (10)
1. Förfarande för produktion av antigena HBV-partiklar vä-sentligen bestäende av S- och preS2-proteiner ur stammen Pichia pastoris, kännetecknat av att det innefattar ' 5 (a) att transformera stammen Pichia pastoris med en första expressionskassett innehällande en strukturgen för S-protein i hepatitis B-virus, funktionellt förbunden med ett 51-regleromrdde som valts i ett AQXl 5’-reglerom-räde isolerat frän Pichia pastoris eller dhas 5’-reg- 10 leromrädet och en 31 -termineringssekvens av Pichia pas toris; och (b) att transformera stammen Pichia pastoris med en andra expressionskassett innehällande preS2-protein av hepatitis B-virus, funktionellt kopplad tili 5'-reglerom- 15 rädet som valts i ett aoxi 5'-regleromräde isolerat frän Pichia pastoris eller dhas 5'-regleromrädet och en 31-termineringssekvens av Pichia pastoris; och därefter (c) att odla den uppkomna transformerade stammen Pichia pastoris under lämpliga förhällanden för att dstadkomma 20 produktion av nämnda HBV-partiklar.
2. Förfarande enligt patentkrav l, kännetecknat av att nämnda transformation utförs med ätminstone en vektor vald i gruppen bestäende av plasmider eller lineära, integrerande, ·· 25 platsspecifikä vektorer.
3. Förfarande enligt patentkrav 2, kännetecknat av att vektorerna är integrerande. 30
4. Förfarande enligt patentkrav 3, kännetecknat av att man använder • * a) en första integrerande platsspecifik vektor innehällan-de följande seriella sekvens: i) ett första insättningsbart DNA-fragment, 35 ii) en markörgen och ätminstone en expressionskassett inne-hällande en strukturgen för preS2, funktionellt förbunden med ett regleromräde och en 3'-termineringssekvens, och 54 104639 iii) ett andra insättningsbart DNA-fragment i vilket den in-bördes ordningen mellan markörgenen och kassetten för markörgenen (ii) kan växlas; b) och en andra integrerande vektor innehällande följande: 5 i) ätminstone ett insättningsbart DNA-fragment, ii) en markörgen och ätminstone en expressionskassett innehällande en strukturgen för S, funktionellt förbunden med regleromrädet och 3'-termineringssekvensen, i vil-ken den inbördes ordningen mellan markörgenen och kas- 10 setten för komponent (ii) kan växlas.
5. Förfarande enligt patentkrav 4, kännetecknat av att nämnda insättningsbara DNA-fragment erhdlls ur DNA-sekvensen i en gen som isolerats frdn Pichia pastoris och väljs i 15 gruppen bestäende av AOX1, p40, DHAS och HIS4.
6. Förfarande enligt patentkrav 4, kännetecknat av att ät-minstone en expressionskassett innefattar a) ett regleromräde valt i gruppen bestäende av AOXl och
20 DHAS isolerad frän Pichia pastoris, funktionellt för- bundet med b) en strukturgen för preS2 eller S, funktionellt förbunden med c) en 3'-termineringssekvens frän Pichia pastoris vald i ;·· 25 gruppen bestäende av 3 ' - termineringssekvenser som iso lerats frän AOXl-genen, p40-genen, DHAS-genen och HIS4-genen.
7. Förfarande enligt patentkrav 4, kännetecknat av att 30 nämnda markörgen väljs i gruppen bestäende av HIS4 och ARG4, som isolerats frän Pichia pastoris, SUC2 som isolerats frän Saccharomyces cerevisiae och neomycin-gen av Tn903 och TnGOl. 1
8. Förfarande enligt patentkrav 4, kännetecknat av att nämnda vektor innehällande en strukturgen för preS2 innefattar 55 1 0 4 6 3 9 a) ett första insättningsbart DNA-fragment vilket är cirka 1 kb av det 5' AOX1 regleromräde som isolerats frän Pichia pastoris, funktionellt förbundet med b) en strukturgen för preS2, funktionellt förbunden med ' 5 c) 3'-termineringssekvensen för AOX1 som isolerats frän Pichia pastoris, ligerad tili d) en markörgen som är HIS4 som isolerats frän Pichia pastoris, ligerad tili e) ett andra insättningsbart DNA-fragment vilket är cirka 10 0,65 kb av 3' AOX1-termineringssekvensen.
9. Förfarande enligt patentkrav 4, kännetecknat av att nämnda vektor innehällande en strukturgen för S innefattar a) ett insättningsbart DNA-fragment vilket är cirka l kb 15 av 5' AOXl-regleromrädet, som isolerats frän Pichia pastoris, funktionellt förbundet med b) en strukturgen för S, funktionellt förbunden med c) 3' AOX1-termineringssekvensen, som isolerats frän Pichia pastoris, ligerad tili 20 d) en markörgen som är ARG4 som isolerats frän Saccharo-myces cerevisiae, ligerad tili e) ett insättningsbart DNA-fragment vilket är cirka 0,65 kb av 3' A0X1-termineringssekvensen. :·· 25
10. Pichia pastoris PPF1 (NRRL Y-18017) i vilken transforme- rats en kopia av expressionskassetten av pTB05A (jfr exempel II) eller Pichia pastoris PPF1 (NRRL Y-18017), i vilken transformerats tvä kopior av en preS2-gen av pTB05A (jfr exempel II) och en kopia av S-genen. * I
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19371488A | 1988-05-13 | 1988-05-13 | |
| US19371488 | 1988-05-13 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI892312A0 FI892312A0 (fi) | 1989-05-12 |
| FI892312A FI892312A (fi) | 1989-11-14 |
| FI104639B true FI104639B (sv) | 2000-03-15 |
Family
ID=22714736
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI892312A FI104639B (sv) | 1988-05-13 | 1989-05-12 | Expression av hepatitis B, S och PreS2 proteiner i metylotropiska jäster |
| FI992546A FI107265B (sv) | 1988-05-13 | 1999-11-29 | Expression av hepatitis B, S och PreS2 proteiner i metylotropiska jäster |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI992546A FI107265B (sv) | 1988-05-13 | 1999-11-29 | Expression av hepatitis B, S och PreS2 proteiner i metylotropiska jäster |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US5650296A (sv) |
| EP (1) | EP0341746B1 (sv) |
| JP (1) | JP2614314B2 (sv) |
| KR (1) | KR100193701B1 (sv) |
| CN (1) | CN1038668A (sv) |
| AT (1) | ATE151109T1 (sv) |
| AU (1) | AU618596B2 (sv) |
| CA (1) | CA1340617C (sv) |
| DD (1) | DD285373A5 (sv) |
| DE (1) | DE68927921T2 (sv) |
| DK (1) | DK235289A (sv) |
| ES (1) | ES2101676T3 (sv) |
| FI (2) | FI104639B (sv) |
| GR (1) | GR3023985T3 (sv) |
| HU (1) | HU207532B (sv) |
| IE (1) | IE81158B1 (sv) |
| IL (1) | IL90161A0 (sv) |
| IN (1) | IN171696B (sv) |
| MX (1) | MX26715A (sv) |
| NO (1) | NO300465B1 (sv) |
| NZ (1) | NZ228948A (sv) |
| PL (1) | PL161997B1 (sv) |
| PT (1) | PT90553A (sv) |
| YU (1) | YU98689A (sv) |
| ZA (1) | ZA893440B (sv) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5032516A (en) * | 1985-10-25 | 1991-07-16 | Phillips Petroleum Company | Pichia pastoris alcohol oxidase II regulatory region |
| PL168408B1 (pl) * | 1989-08-03 | 1996-02-29 | Smithkline Beecham Biolog | Sposób wytwarzania stransformowanego mikroorganizmu PL |
| GB9007416D0 (en) * | 1990-04-02 | 1990-05-30 | Wellcome Found | Expression of heterologous protein in yeast |
| US6197548B1 (en) | 1990-04-02 | 2001-03-06 | Medeva Pharma Limited | Transformed Pichia expressing the pertactin antigen |
| EP0521348A1 (en) * | 1991-06-18 | 1993-01-07 | Korea Institute Of Science And Technology | Chimeric antibody with specificity for hepatitis B virus pre-S2 surface antigen and cell line producing same |
| LT3988B (en) | 1992-02-17 | 1996-06-25 | Fermentas Biotech Inst | Recombinant plasmides pfs19, pfps2-48 and pjlfds1 codingsynthesis of human hepatite b of surfice virus antigenes, methods fof producing thereof |
| CA2101610A1 (en) * | 1992-08-07 | 1994-02-08 | William D. Prevatt | Production of bacillus entomotoxins in methylotrophic yeast |
| GB9402832D0 (en) * | 1994-02-15 | 1994-04-06 | Smith Kline Beecham Biolog S A | Novel process |
| US5716808A (en) * | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
| US5955349A (en) * | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| EP0862640A2 (en) * | 1995-11-09 | 1998-09-09 | ZymoGenetics, Inc. | Production of gad65 in methylotrophic yeast |
| MX9605082A (es) | 1996-10-24 | 1998-04-30 | Univ Autonoma De Nuevo Leon | Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano. |
| WO2006033679A2 (en) * | 2004-05-25 | 2006-03-30 | Chimeracore, Inc. | Self-assembling nanoparticle drug delivery system |
| CN1704475A (zh) * | 2004-05-31 | 2005-12-07 | 成都生物制品研究所 | 羧端含前s2免疫决定簇的乙肝表面抗原融合基因及蛋白质 |
| JP2008507266A (ja) * | 2004-07-22 | 2008-03-13 | グライコフィ， インコーポレイテッド | ピチアにおける異種遺伝子発現のためのリンゴ酸シンターゼ調節配列 |
| CN100381171C (zh) * | 2004-12-30 | 2008-04-16 | 成都生物制品研究所 | 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒 |
| ATE460922T1 (de) * | 2006-04-07 | 2010-04-15 | Chimeros Inc | Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen |
| AU2008236566A1 (en) * | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
| WO2013036973A2 (en) | 2011-09-09 | 2013-03-14 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
| EP4357457B1 (en) | 2012-10-23 | 2024-10-16 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR76274B (sv) * | 1981-08-04 | 1984-08-04 | Univ California | |
| EP0401941A3 (en) * | 1984-07-11 | 1991-04-17 | Takeda Chemical Industries, Ltd. | Hepatitis b virus surface antigen and production thereof |
| US4895800A (en) * | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
| US4816564A (en) * | 1986-01-31 | 1989-03-28 | Merck & Co., Inc. | Method for producing hepatitis B virus proteins in yeast |
| JPS62236496A (ja) * | 1986-04-07 | 1987-10-16 | Green Cross Corp:The | ＨＢｓＡｇの製造方法 |
| US4963483A (en) * | 1987-10-13 | 1990-10-16 | Merck & Co., Inc. | Method for producing hepatitis B virus proteins in yeast |
| NZ228774A (en) * | 1988-04-25 | 1991-05-28 | Phillips Petroleum Co | Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells |
-
1989
- 1989-05-02 IL IL90161A patent/IL90161A0/xx unknown
- 1989-05-02 NZ NZ228948A patent/NZ228948A/en unknown
- 1989-05-09 ZA ZA893440A patent/ZA893440B/xx unknown
- 1989-05-11 HU HU892372A patent/HU207532B/hu not_active IP Right Cessation
- 1989-05-11 NO NO891921A patent/NO300465B1/no not_active IP Right Cessation
- 1989-05-11 KR KR1019890006430A patent/KR100193701B1/ko not_active IP Right Cessation
- 1989-05-12 MX MX2671589A patent/MX26715A/es unknown
- 1989-05-12 ES ES89108632T patent/ES2101676T3/es not_active Expired - Lifetime
- 1989-05-12 EP EP89108632A patent/EP0341746B1/en not_active Expired - Lifetime
- 1989-05-12 DD DD89328581A patent/DD285373A5/de unknown
- 1989-05-12 AU AU34734/89A patent/AU618596B2/en not_active Expired
- 1989-05-12 DE DE68927921T patent/DE68927921T2/de not_active Expired - Lifetime
- 1989-05-12 DK DK235289A patent/DK235289A/da not_active Application Discontinuation
- 1989-05-12 AT AT89108632T patent/ATE151109T1/de not_active IP Right Cessation
- 1989-05-12 PT PT90553A patent/PT90553A/pt not_active Application Discontinuation
- 1989-05-12 PL PL89279426A patent/PL161997B1/pl unknown
- 1989-05-12 IE IE156389A patent/IE81158B1/en not_active IP Right Cessation
- 1989-05-12 YU YU98689A patent/YU98689A/sh unknown
- 1989-05-12 FI FI892312A patent/FI104639B/sv active IP Right Grant
- 1989-05-13 CN CN89103330A patent/CN1038668A/zh active Pending
- 1989-05-15 CA CA000599724A patent/CA1340617C/en not_active Expired - Lifetime
- 1989-05-15 JP JP1121313A patent/JP2614314B2/ja not_active Expired - Fee Related
- 1989-05-22 IN IN388/CAL/89A patent/IN171696B/en unknown
-
1995
- 1995-06-06 US US08/467,660 patent/US5650296A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,345 patent/US5670630A/en not_active Expired - Lifetime
-
1997
- 1997-07-02 GR GR970401639T patent/GR3023985T3/el unknown
-
1999
- 1999-11-29 FI FI992546A patent/FI107265B/sv not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI104639B (sv) | Expression av hepatitis B, S och PreS2 proteiner i metylotropiska jäster | |
| FI95929B (sv) | Framställning av hepatitis B ytantigen i jäst | |
| FI94427B (sv) | Regleringsregion för heterologisk genexpression i jäst | |
| US5133961A (en) | Vaccines comprising yeast-derived hepatits b virus polypeptides | |
| FI80720B (fi) | Saccharmyces cerevisiae-hybridvektorer och deras anvaendning foer framstaellning av plypeptider. | |
| JPH0380083A (ja) | 新規な抗原物質及びその製法 | |
| IE65996B1 (en) | Synthesis of human virus antigens by yeast | |
| EP0103201B1 (en) | Shuttle vector | |
| US4803164A (en) | Preparation of hepatitis b surface antigen in yeast | |
| AU605036B2 (en) | Expression of hepatitis B2 pres protein in methylothrophic yeasts | |
| US4983520A (en) | DNA sequence encoding modified hepatitis B virus surface antigen P31 protein | |
| US5164485A (en) | Modified hepatitis B virus surface antigen P31 and production thereof | |
| EP0251460B1 (en) | Method for producing hepatitis b virus core antigen (hbcag) in yeast | |
| PL168408B1 (pl) | Sposób wytwarzania stransformowanego mikroorganizmu PL | |
| KR900005534B1 (ko) | 복합 프로모터를 이용한 효모 발현 벡터에 의한 b형 간염 바이러스 표면항원들의 제조방법 | |
| EP0277770A1 (en) | Alpha-mating factor promoter is modified by deleting pre-pro secretory leader sequence | |
| IE903178L (en) | Synthesis of human virus antigens by yeast |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assigment of application |
Owner name: RESEARCH CORPORATION TECHNOLOGIES, INC. |
|
| FG | Patent granted |
Owner name: RESEARCH CORPORATION TECHNOLOGIES, INC. |